Genetic mutation lowers coronary heart disease risk through lifelong LDL reduction, suggesting new prevention strategies.
People with a mutation in a proteolytic enzyme are at a substantially lower risk for coronary heart disease because of their lifelong reduction of plasma low-density lipoprotein.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: